Concepts (177)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vesico-Ureteral Reflux | 3 | 2024 | 87 | 1.460 |
Why?
|
| Prostatic Neoplasms | 15 | 2019 | 1599 | 1.220 |
Why?
|
| Bladder Exstrophy | 2 | 2023 | 12 | 1.040 |
Why?
|
| Prostatectomy | 10 | 2019 | 356 | 1.010 |
Why?
|
| Carcinoma, Transitional Cell | 6 | 2016 | 187 | 0.930 |
Why?
|
| Urinary Bladder Neoplasms | 7 | 2016 | 541 | 0.800 |
Why?
|
| Hemangioma | 1 | 2023 | 96 | 0.770 |
Why?
|
| Ureter | 3 | 2020 | 100 | 0.720 |
Why?
|
| Urogenital Abnormalities | 1 | 2023 | 168 | 0.720 |
Why?
|
| Lymph Nodes | 4 | 2017 | 397 | 0.660 |
Why?
|
| Robotic Surgical Procedures | 2 | 2020 | 234 | 0.600 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2016 | 1312 | 0.580 |
Why?
|
| Lymph Node Excision | 4 | 2014 | 176 | 0.540 |
Why?
|
| Decision Support Techniques | 2 | 2013 | 318 | 0.390 |
Why?
|
| Cell Cycle Proteins | 1 | 2016 | 699 | 0.380 |
Why?
|
| Prune Belly Syndrome | 2 | 2024 | 5 | 0.370 |
Why?
|
| Biomarkers, Tumor | 3 | 2016 | 1697 | 0.350 |
Why?
|
| Models, Biological | 1 | 2016 | 1530 | 0.350 |
Why?
|
| Cystectomy | 4 | 2016 | 166 | 0.340 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 315 | 0.320 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 965 | 0.270 |
Why?
|
| Lymphatic Metastasis | 7 | 2017 | 450 | 0.250 |
Why?
|
| Retrospective Studies | 17 | 2024 | 17579 | 0.250 |
Why?
|
| Prognosis | 9 | 2016 | 5052 | 0.250 |
Why?
|
| Neoplasm Staging | 8 | 2017 | 1375 | 0.230 |
Why?
|
| Nephrectomy | 3 | 2020 | 181 | 0.230 |
Why?
|
| Neoplasm Grading | 5 | 2018 | 307 | 0.220 |
Why?
|
| Treatment Outcome | 11 | 2024 | 13101 | 0.220 |
Why?
|
| Aged | 20 | 2019 | 21584 | 0.210 |
Why?
|
| Humans | 36 | 2024 | 133529 | 0.210 |
Why?
|
| Urologic Surgical Procedures | 1 | 2023 | 59 | 0.210 |
Why?
|
| Pelvis | 2 | 2014 | 73 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 3869 | 0.200 |
Why?
|
| Priapism | 1 | 2022 | 12 | 0.190 |
Why?
|
| Male | 29 | 2024 | 65657 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 4 | 2018 | 675 | 0.190 |
Why?
|
| Proportional Hazards Models | 5 | 2017 | 1467 | 0.180 |
Why?
|
| Myelitis, Transverse | 1 | 2021 | 6 | 0.180 |
Why?
|
| Intermittent Urethral Catheterization | 1 | 2021 | 9 | 0.180 |
Why?
|
| Prostate | 3 | 2018 | 449 | 0.180 |
Why?
|
| Urinary Retention | 1 | 2021 | 19 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 1136 | 0.170 |
Why?
|
| Denys-Drash Syndrome | 1 | 2020 | 5 | 0.170 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2021 | 46 | 0.170 |
Why?
|
| Middle Aged | 18 | 2018 | 29081 | 0.170 |
Why?
|
| Disorders of Sex Development | 1 | 2020 | 72 | 0.170 |
Why?
|
| Spinal Dysraphism | 1 | 2024 | 274 | 0.170 |
Why?
|
| Renal Artery | 1 | 2020 | 70 | 0.160 |
Why?
|
| Replantation | 1 | 2020 | 57 | 0.160 |
Why?
|
| Kidney Neoplasms | 2 | 2014 | 460 | 0.150 |
Why?
|
| Prostatic Hyperplasia | 1 | 2019 | 118 | 0.150 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 44 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2022 | 346 | 0.140 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2020 | 224 | 0.140 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 194 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 1468 | 0.140 |
Why?
|
| Penile Neoplasms | 1 | 2017 | 36 | 0.140 |
Why?
|
| Penis | 2 | 2017 | 103 | 0.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2017 | 72 | 0.140 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2018 | 154 | 0.140 |
Why?
|
| Penile Erection | 2 | 2015 | 87 | 0.130 |
Why?
|
| Disease Progression | 4 | 2016 | 2249 | 0.130 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2017 | 97 | 0.130 |
Why?
|
| Formaldehyde | 1 | 2017 | 39 | 0.130 |
Why?
|
| Printing, Three-Dimensional | 1 | 2017 | 70 | 0.130 |
Why?
|
| Androgen Antagonists | 1 | 2017 | 134 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2017 | 131 | 0.130 |
Why?
|
| Models, Anatomic | 1 | 2017 | 104 | 0.130 |
Why?
|
| Abnormalities, Multiple | 1 | 2022 | 982 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2017 | 5453 | 0.130 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 236 | 0.120 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2016 | 55 | 0.120 |
Why?
|
| Registries | 3 | 2017 | 1591 | 0.120 |
Why?
|
| BCG Vaccine | 1 | 2016 | 112 | 0.120 |
Why?
|
| Cryosurgery | 1 | 2015 | 47 | 0.110 |
Why?
|
| Erectile Dysfunction | 2 | 2015 | 213 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 1 | 2016 | 392 | 0.110 |
Why?
|
| Female | 13 | 2024 | 71560 | 0.110 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 1 | 2014 | 37 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2016 | 620 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 318 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 119 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2014 | 61 | 0.100 |
Why?
|
| Infant, Newborn | 2 | 2024 | 8633 | 0.100 |
Why?
|
| Ureteral Neoplasms | 1 | 2013 | 27 | 0.100 |
Why?
|
| Medical Audit | 1 | 2013 | 104 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 318 | 0.100 |
Why?
|
| Child | 6 | 2024 | 25888 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 786 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 1 | 2013 | 150 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2018 | 6586 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2014 | 251 | 0.090 |
Why?
|
| Carcinoma | 1 | 2013 | 308 | 0.080 |
Why?
|
| Muscle, Smooth | 2 | 2024 | 133 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2018 | 3097 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2016 | 3725 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 760 | 0.080 |
Why?
|
| Phenotype | 1 | 2018 | 4581 | 0.070 |
Why?
|
| Urinary Bladder | 2 | 2022 | 253 | 0.070 |
Why?
|
| Biomarkers | 1 | 2016 | 3417 | 0.060 |
Why?
|
| Administration, Intravesical | 2 | 2016 | 33 | 0.060 |
Why?
|
| Muscle Contraction | 1 | 2024 | 163 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 2 | 2015 | 272 | 0.050 |
Why?
|
| Biopsy | 2 | 2018 | 1298 | 0.050 |
Why?
|
| Genitalia | 1 | 2022 | 39 | 0.050 |
Why?
|
| Urethra | 1 | 2022 | 90 | 0.050 |
Why?
|
| Phenylephrine | 1 | 2022 | 39 | 0.050 |
Why?
|
| Ion Channels | 1 | 2024 | 209 | 0.050 |
Why?
|
| Survival Rate | 2 | 2017 | 2203 | 0.040 |
Why?
|
| Obesity | 1 | 2013 | 2438 | 0.040 |
Why?
|
| Electrolytes | 1 | 2020 | 55 | 0.040 |
Why?
|
| Proteinuria | 1 | 2020 | 111 | 0.040 |
Why?
|
| Writing | 1 | 2020 | 66 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 198 | 0.040 |
Why?
|
| Adolescent | 3 | 2024 | 20605 | 0.040 |
Why?
|
| Angiography | 1 | 2020 | 212 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2014 | 1749 | 0.040 |
Why?
|
| Urology | 1 | 2020 | 86 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 191 | 0.040 |
Why?
|
| Risk Factors | 4 | 2016 | 10970 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2017 | 7197 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 246 | 0.040 |
Why?
|
| Operative Time | 1 | 2019 | 189 | 0.040 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2018 | 29 | 0.040 |
Why?
|
| Cryptorchidism | 1 | 2018 | 37 | 0.040 |
Why?
|
| Length of Stay | 1 | 2024 | 1398 | 0.040 |
Why?
|
| Abdominal Wall | 1 | 2018 | 36 | 0.040 |
Why?
|
| Inguinal Canal | 1 | 2017 | 13 | 0.040 |
Why?
|
| Orchiectomy | 1 | 2017 | 53 | 0.030 |
Why?
|
| Adult | 4 | 2022 | 31787 | 0.030 |
Why?
|
| Health Facilities | 1 | 2017 | 67 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 169 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 1037 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 2310 | 0.030 |
Why?
|
| Disinfection | 1 | 2017 | 29 | 0.030 |
Why?
|
| Infant | 2 | 2024 | 13257 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2017 | 78 | 0.030 |
Why?
|
| United States | 3 | 2017 | 11761 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2017 | 336 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 263 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 398 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 788 | 0.030 |
Why?
|
| Cryotherapy | 1 | 2015 | 21 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2024 | 14904 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3668 | 0.030 |
Why?
|
| Hospitalization | 1 | 2024 | 1912 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2016 | 258 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2017 | 373 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2017 | 400 | 0.030 |
Why?
|
| Aspirin | 1 | 2016 | 232 | 0.030 |
Why?
|
| Mortality | 1 | 2016 | 260 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 93 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1463 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1584 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 504 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2153 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2014 | 328 | 0.030 |
Why?
|
| Kidney | 1 | 2020 | 1382 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1973 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 448 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2014 | 463 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2014 | 404 | 0.020 |
Why?
|
| Pediatrics | 1 | 2020 | 1218 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 1256 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 809 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 3042 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1347 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 414 | 0.020 |
Why?
|
| Disease Management | 1 | 2014 | 569 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 6332 | 0.020 |
Why?
|
| Decision Making | 1 | 2014 | 702 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2018 | 5205 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1305 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 1354 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2956 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2017 | 2595 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 1854 | 0.010 |
Why?
|